These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 19021720)

  • 21. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
    Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
    Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.
    Massenkeil G; Nagy M; Neuburger S; Tamm I; Lutz C; le Coutre P; Rosen O; Wernecke KD; Dörken B; Arnold R
    Bone Marrow Transplant; 2005 Oct; 36(8):683-9. PubMed ID: 16113673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplantation in patients with myelodysplastic syndrome: outcome analysis according to the International Prognostic Scoring System.
    Rubio S; Martins C; Lacerda JF; Carmo JA; Lourenço F; Lacerda JM
    Acta Med Port; 2006; 19(5):343-7. PubMed ID: 17376319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of hematopoietic cell transplantation as therapy for myelodysplasia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):541-7. PubMed ID: 22127318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
    Solomon SR; Savani BN; Childs R; Montero A; Boss C; Read EJ; Leitman SF; Barrett AJ
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):619-26. PubMed ID: 16041312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
    Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias.
    De Witte T
    Int J Hematol; 2000 Aug; 72(2):151-6. PubMed ID: 11039662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
    Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
    Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia.
    Bitan M; Or R; Shapira MY; Resnick IB; Gesundheit B; Ackerstein A; Samuel S; Elad S; Slavin S
    Bone Marrow Transplant; 2008 Jan; 41(1):69-78. PubMed ID: 17994125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
    Chevallier P; Labopin M; Nagler A; Ljungman P; Verdonck LF; Volin L; Zander AR; Finke J; Socie G; Cordonnier C; Harousseau JL; Mohty M; Rocha V;
    Bone Marrow Transplant; 2009 Nov; 44(9):589-94. PubMed ID: 19349953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
    Ayas M; Al-Seraihi A; Al-Mahr M; Al-Jefri A; Belgaumi A; Elhassan I; El-Solh H
    Pediatr Blood Cancer; 2006 Dec; 47(7):926-30. PubMed ID: 16425264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant outcome in chronic myeloid leukaemia.
    Raza S; Ullah K; Ahmed P; Khan B; Kamal MK
    J Coll Physicians Surg Pak; 2008 Oct; 18(10):615-9. PubMed ID: 18940118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
    de Lima M; Giralt S
    Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity and outcome of children with treatment related acute myeloid leukemia.
    Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D
    Pediatr Blood Cancer; 2008 Jan; 50(1):17-23. PubMed ID: 17252569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.